The future trajectory of the Hemangioblastoma market is anticipated to show steady but specialized expansion, primarily fueled by advancements in molecular diagnostics and the introduction of targeted drug therapies. A critical driver is the growing understanding of the Von Hippel-Lindau (VHL) pathway, where a defective VHL protein leads to the uncontrolled proliferation of stromal and...